Background. We hypothesized that (1) endogenous adenosine released during ischemia/reperfusion reduces infarct size and preserves postischemic myocardial blood flow by receptor-mediated mechanisms and (2) this cardioprotection is exerted predominantly during reperfusion.
myocardium, adenosine accumulates secondary to the rapid hydrolysis of ATP and limited washout despite adenosine-induced vasodilation.34 Recent evidence shows that adenosine may be involved in counteracting other deleterious events during ischemia and reperfusion independent of its vasodilator properties. Adenosine inhibits platelet aggregations and attenuates neutrophil activities, including intravascular accumulation,6-8 superoxide generation,9,10 and neutrophil-mediated endothelial cell damage."1 Neutrophil activation and accumulation may be key in the pathogenesis of ischemia/reperfusion injury.'2 The exogenous administration of pharmacological doses of adenosine or receptor subtype-specific analogues has been effective in reducing endothelial damage6 and in diminish-ing both the early and late development of myocardial necrosis.6-8 These cardioprotective effects of exogenously applied adenosine are receptor mediated13-16 and can be exerted whether administration of adenosine or its analogues precedes the ischemic event1314 or is confined to the reperfusion phase. 6-8'15 The effects of exogenous adenosine on inflammatory processes may be related to the relatively high doses given, with a potential for expression of well-established side effects.2 Although intravascular administration of adenosine-related agents may compensate for rapid plasma degradation and allow supraphysiological levels to build up in the blood, the endothelium may impose a formidable barrier to the extravascular distribution of exogenous adenosine, thereby limiting exposure of myocytes to the purine.
Recently, Toombs et a113 demonstrated that endogenous adenosine released by the ischemic myocardium contributed significantly to attenuation of infarct development, suggesting an inherent protection by the endogenous autacoid. This cardioprotective role for endogenous adenosine is not an intuitive one, since endogenous adenosine is removed from the proximity of the myocyte by rapid degradation via adenosine deaminase or transportation into the endothelium or is quickly washed out during reperfusion. Although the effects of pharmacological doses of exogenously administered adenosine or its analogues have been avidly investigated, the cardioprotection conferred by endogenous adenosine released during ischemia and reperfusion and the time course of this protection have not been investigated. This is an important question because endogenous adenosine has ready access to the interstitial space surrounding myocytes but is rapidly catabolized or washed out. The present study tests the hypotheses that (1) endogenous adenosine released during ischemia reduces ischemia/reperfusion injury by receptor-mediated mechanisms and (2) this cardioprotection is exerted during reperfusion. Methods Surgical Preparation ofAnimals Male New Zealand White rabbits weighing 4 to 5 kg were anesthetized with an injection of ketamine HCl (35 mg/kg IM) and xylazine (6 mg/kg IM). Additional anesthesia (100 mg/mL ketamine plus 2 mg/mL xylazine IV) was continuously administered during the experiment by a Harvard infusion pump at 1.3 mL/h. The neck was opened with a ventral middle incision, and the trachea was intubated. The rabbits were mechanically ventilated on a volume-cycled respirator (Edco Scientific, Chapel Hill, NC) with oxygen-enriched room air. Ventilation rate was adjusted to 30 to 35 breaths per minute, and tidal volume was approximately 15 mL. The respiratory rate was adjusted to maintain blood pH in the physiological range. Acidosis was counteracted with intravenous sodium bicarbonate as necessary. Catheters were placed in the right femoral artery for the measurement of blood pressure and in the femoral vein for infusion of drug and fluids. Lead II of the ECG was monitored throughout the study. The chest was exposed by median sternotomy, and the pericardium was opened to expose the heart. A high-fidelity transducer-tipped catheter (model MPC-500, Millar Instruments, Houston, Tex) was introduced into the left ventricular (LV) cavity via a small puncture wound in the apex. The position of the transducer was confirmed by the LV pressure waveform and secured in place by a pursestring suture. A catheter was secured in the left atrium for injection of radioactive microspheres. A 4-0 silk thread with a taper needle was passed around a branch of the left coronary artery, and the ends of the tie were threaded through a small plastic (PE90) tube to form a snare. All animals were then systemically heparinized with 300 units/kg sodium heparin before the experiment was begun.
Nonselective A1-A2 receptor antagonists, 8-p-sulfophenyltheophylline (SPT; Research Biochemicals, Inc, Natick, Mass) and PD115,199 (a gift from Dr. Kim Gallagher, Parke-Davis, Warner-Lambert Co, Ann Arbor, Mich) were prepared by mixing the powder with 5 mL of 0.9% saline at 37°C just before injection. A dose of 10 mg/kg body weight for SPT was used to block adenosine receptors.13 To select the dose of PD115, 199 to block adenosine interaction with receptors, we tested the effects of PD115,199 on the changes in heart rate and blood pressure caused by adenosine infusion in three rabbits under P-blockade with 1.5 mg/kg metoprolol. We found that intravenous PD115,199 at a dose of 6 mg/kg body weight totally blocked the decrease in heart rate and blood pressure 2 minutes before injection of adenosine and continuously maintained its effects on adenosine receptors for 2 hours.
Experimental Protocol
After a 20to 30-minute postsurgical stabilization period, all rabbits were randomly divided into six groups: (1) saline Vehicle group (n=10): Rabbits received saline infusion before coronary occlusion to allow endogenously released adenosine to interact with receptors during ischemia and reperfusion; (2) SPTIR group (n= 10): SPT was injected 2 minutes before coronary occlusion to block endogenous adenosine receptor-mediated events during both ischemia and reperfusion; (3) MSPTIR group (n=11): SPT was administered 2 minutes before coronary occlusion in multiple doses given every 20 minutes over a period of 60 minutes to block adenosine receptors for the entire period of ischemia and reperfusion; (4) SPTR group (n= 10): SPT was given 2 minutes before reperfusion to block adenosine receptors only during the reperfusion period, thereby allowing adenosine receptor stimulation to occur during ischemia; (5) SPT3OR group (n=10): SPT was injected after 30 minutes of reperfusion so that adenosine receptors could be stimulated during ischemia and the first 30 minutes of reperfusion; (6) PDR group (n=10): PD115,199 was administered 2 minutes before reperfusion to evaluate the cardioprotective effects of endogenous adenosine during the reperfusion period.
A schematic of the protocol is depicted in Fig 1. First, steady-state baseline hemodynamic measurements were acquired in duplicate. Myocardial blood flow to the left ventricle was determined with radiolabeled 15-,um tracer microspheres using the reference sampling withdrawal method as previously described. 13 Microspheres labeled with 95Nb, 85Sr, 141Ce, 51Cr, and ll3Sn were sonicated and vortexed to ensure their even distribution in the suspending medium. Approximately 0.5 to 1x 106 microspheres were injected into the left atrial catheter. The 30 minutes, followed by 120 minutes of reperfusion. 8-p-Sulfophenyltheophylline (SPT) was given either as a single bolus dose at the onset of ischemia (SPTIR), at the onset of reperfusion (SPTR), 30 minutes after the onset of reperfusion (SPT3OR), or in multiple doses during the period of ischemia and early reperfusion (MSPTIR). PD115,199 was given at the onset of reperfusion (PDR). *Hemodynamic data were acquired and microspheres injected to measure myocardial blood flow at these points.
changes in blood pressure. Arterial reference blood samples were withdrawn via the right femoral artery catheter at a steady rate of 3.25 mL/min for a total of 2 minutes by a constant-speed pump. Normal saline (4 mL IV) was infused to replace blood volume removed during reference sampling. In all six groups, the left coronary artery was reversibly occluded by pulling up on the snare to produce a zone of regional ischemia in the left ventricle as visually confirmed by cyanosis and dyskinesis. Lidocaine was not given in any experiment. Hemodynamic data were acquired in duplicate, and microspheres were administered at the end of 30 minutes of ischemia. The left coronary artery snare was then released to begin 120 minutes of reperfusion. Hemodynamic measurements were repeated, and microspheres were administered after 15, 60, and 120 minutes of reperfusion, as shown in Fig 1 .
The experimental procedures complied with the "Guiding Principles in the Use and Care of Animals" approved by the Council of the American Physiological Society as well as with state and federal regulations. The experimental protocol was approved by the institutional Animal Care and Use Committee.
Data Acquisition
Left ventricular and arterial pressures were digitized at 250 Hz with a 12-bit analog-to-digital converter (Data Translation model DT 2821, Marlborough, Mass) and stored on hard disk. Using a videographics program developed in our laboratory, the instantaneous first derivative of the LV pressure (dP/dt) was calculated by computer algorithm. The data were divided into cardiac cycles with the end-diastolic point identified when positive dP/dt exceeded 200 mm Hg/s during isovolumic systole, and end systole was identified 20 msec before peak negative dP/dt. Pressure waveforms were visually displayed, end systole and end diastole were manually adjusted if necessary, and dysrhythmic beats were excluded. Heart rate, peak LV pressure, end-diastolic LV pressure, and mean arterial pressure were averaged, as well as output from no less than 15 beats. Pressure-rate product, used as an index of myocardial oxygen demand, was calculated as the product of heart rate and peak LV systolic pressure.
Determination ofArea at Risk and Infarct Size
At the end of the reperfusion period, the snare around the coronary artery was retightened, and 4 to 5 mL of Unisperse blue dye (CIBA-GEIGY Inc, Newport, Del) was injected into the left atrium to stain the normally perfused region blue. The area at risk (Ar) was demarcated by the lack of blue staining. Rabbits were killed with a lethal dose of 50 mg/mL sodium pentobarbital, and the heart was rapidly removed. The atria, right ventricle, and great vessels were subsequently removed, and the LV was cut parallel to the atrioventricular sulcus from apex to base into slices 2 mm thick. The unstained region of myocardium (the Ar) was separated from the blue-stained nonischemic zone and incubated for 15 minutes in a 1% solution of triphenyltetrazolium chloride (TTC) in phosphate buffer (pH 7.4) warmed to 370C. In the presence of intact dehydrogenase enzyme systems or NADW/NADH, TTC dye forms red precipitates demarcating nonnecrotic tissue. Areas of necrosis lack these components and therefore remain a pale color. At the end of the TTC incubation period, tissue samples were placed into a 10% solution of cold buffered formalin overnight for fixation. Approximately 1 mm on either side of the Ar/nonischemic border was trimmed and analyzed separately as risk border zone and nonrisk border zone, respectively. The Ar was then subdivided into nonnecrotic (TTC-positive, red) and areas of necrosis (A.) (TTC-negative, pale). Border zone tissue was included in its respective A, determinations. Very small sections of myocardium remote from the A, that necrosed because of placement of the intraventricular catheter and coronary snare were discarded. The A, and A, were determined gravimetrically as described previously.13 The A, as a percent of the LV mass (Ar/LV) was calculated as [(weight of nonnecrotic and necrotic tissue in the risk region)/(total weight of LV)] x 100. The A, as a percent of the LV mass (AJ/LV) was calculated as [(weight of necrotic tissue in area at risk)/(weight of LV)] x 100. A, as a percent of the A, (An/Ar) was calculated as [(weight of necrotic tissue in the risk region)/(total Ar)] x 100.
Regional Myocardial Blood Flow
The nonnecrotic, necrotic, and nonischemic myocardial samples were placed in tared vials marked according to their anatomic location and staining pattern. Tissues and reference blood samples were analyzed for radioactivity in a well-type counter with a 3-in sodium iodide crystal (LKB Wallac, Turku, Finland). Myocardial blood flow was calculated by the reference sample technique.17 Microsphere blood flow data were analyzed with an interactive computer program developed in our laboratory.13'18
Criteria for Exclusion
Standard exclusion criteria were (1) transmural collateral blood flow in the transmural Ar during ischemia exceeding 15 mL. min-l* 100 g-1, (2) unclear demarcation of the Ar after coronary occlusion by Unisperse blue staining, (3) ventricular fibrillation that did not spontaneously convert after 1 minute, and (4) failure to complete the entire protocol. Data from 61 rabbits are included in the final analysis and are reported in this study.
Statistical Analysis
ANOVA for repeated measures was used to determine whether timeand group-related differences existed. If a significant group/time interaction was found, Duncan's multiple range test adjusting for baseline levels was applied to locate the sources of differences. Multiple comparisons were corrected as appropriate using Holm's multiple rejective method to constrain the overall level of probability to P<.05.19 A one-way ANOVA was used to analyze group differences in infarct size. Means and SEM are reported.
Results
Eighty-three rabbits were initially entered into the study. Twelve rabbits were excluded because of excessive blood flow in the A, >15 mL* min-l. 100 g`(two in Vehicle, two in SPTIR, two in MSPTIR, two in SPTR, three in SPT30R, one in PDR) because of collateral blood flow or errors in differentiating ischemic from nonischemic tissue. Seven were excluded for intractable ventricular fibrillation (one in Vehicle, two in SPTIR, two in MSPTIR, one in SPT3OR, one in PDR); three were excluded because of failure of the snare to release at reperfusion. Data were analyzed on the remaining 61 rabbits: 10 rabbits in the Vehicle group, 10 in the SPTIR group, 11 in the MSPTIR group, 10 in the SPTR group, 10 in the SPT3OR group, and 10 in the PDR group.
Hemodynamics
Hemodynamic data during the course of the experiment are summarized in Table 1 . Thirty minutes of coronary occlusion resulted in significant increases in heart rate in all six groups, with no significant group differences during ischemia or any subsequent time period. Mean arterial pressure decreased in all groups during the coronary occlusion period but remained relatively stable thereafter. Peak LV pressure also declined significantly during ischemia, with no group differences, and remained stable thereafter. LV end-diastolic pressure increased significantly in all groups during ischemia, but these increases were resolved by 120 minutes of reperfusion. Positive dP/dt decreased significantly in all six groups during ischemia and 15 minutes of reperfusion in most groups; dP/dt decreased to significantly lower values during 15 minutes of reperfusion in SPTIR and SPT3OR groups. dP/dt decreased further by 120 minutes of reperfusion in SPTIR, MSPTIR, and SPT3OR groups. The pressure-rate product remained stable during the period of coronary occlusion, the increased heart rate counterbalancing the decrease in blood pressure sustained during this period.
Myocardial Blood Flow
Transmural myocardial blood flow in the A, is summarized in Table 2 . All groups were comparable at baseline. Coronary occlusion resulted in significant blood flow reductions of approximately 97% from baseline, which were statistically similar among all six significant increase in transmural blood flow in all groups at 15 minutes of reperfusion relative to values at ischemia. However, blood flow was significantly blunted in the MSPTIR, SPTIR, SPTR, and PDR groups (P<.05), in which adenosine receptors were blocked at this time, compared with the Vehicle and SPT3OR groups. By 60 minutes of reperfusion, hyperemia had significantly decreased in all groups relative to the 15-minute time point. However, transmural blood flow was significantly lower in the SPTIR, MSPTIR, SPTR, and PDR groups compared with the Vehicle group, in which transmural blood flow was still 9% greater than baseline values. After 120 minutes of reperfusion, transmural blood flow in the Vehicle group was near control levels. In contrast, the SPTIR, MSPTIR, and SPTR groups, as well as the PDR group, showed significant hypoperfusion relative to the Vehicle group. This hypoperfusion was significantly greater and near Vehicle levels when adenosine receptors remained unblocked for the first 30 minutes of reperfusion (SPT3OR group). Therefore, antagonism of adenosine receptors with SPT at ischemia or the entire period of reperfusion (1) blunted reactive hyperemia 15 minutes after release of the occlusion and (2) resulted in a "low-reflow" state by 120 minutes of reperfusion; blockade of adenosine receptors after 30 minutes of reperfusion had no effect on blood flow relative to Vehicle.
Distribution of myocardial blood flow to the nonnecrotic and necrotic zones of the A, as well as to the nonischemic zone is shown in Fig 2 for Vehicle, MSPTIR, SPTR, and SPT3OR groups and in Table 3 for SPTIR and PDR groups. Blood flow in the nonischemic myocardium remained unchanged during the course of the experiment. In the nonnecrotic Ar, which consisted primarily of midmyocardial, subepicardial, and lateral margin tissue, ischemia caused a significant (P<.0001) reduction in blood flow to comparable levels in all six groups. At 15 minutes of reperfusion, there was a significant hyperemic blood flow to the nonnecrotic Ar, with a strong tendency (P=.08)
for blood flow to be greater in the Vehicle group compared with the remaining five groups. Blood flow to the nonnecrotic risk region in the Vehicle and SPT3OR groups remained significantly greater after 60 and 120 minutes of reperfusion, whereas there was a continued decline in the other SPT and PD115,199-treated groups to values less than Vehicle and SPT3OR groups. In the necrotic tissue of the Ar, blood flow at 60 minutes and 120 minutes of reperfusion was significantly higher in the Vehicle and SPT3OR groups and lower in all four groups receiving SPT and PD115,199 during ischemia or the entire period of reperfusion (Fig 2, Table 3 ).
Myocardial Infarct Size
The masses of the LV, the Ar, and the A. ( be greater (P<.10) in the MSPTIR group than in the SPTR group. In contrast, a delay in adenosine receptor blockade until after the first 30 minutes of reperfusion resulted in a significantly smaller mass of necrotic tissue relative to the SPTIR, MSPTIR, and SPTR groups, which was comparable to the Vehicle groups. Blockade of adenosine receptors by PD115,199 only during reperfusion (PDR) increased the mass of necrotic tissue over that in the Vehicle group, but this was not a significant difference. When SPT was given as a single bolus before ischemia (SPTIR group), infarct size (An/Ar) was significantly increased over Vehicle, by 52%. Infarct size was significantly greater when SPT was given in multiple doses (MSPTIR group) compared with the single-dose group and was twofold greater than in the Vehicle group. When SPT and PD115,199 were administered at the onset of reperfusion (SPTR and PDR groups), the resulting An/Ar was significantly greater in both groups compared with the Vehicle group but less than the MSPTIR group. However, when adenosine receptor stimulation was allowed to occur during ischemia and for the first 30 minutes of reperfusion (SPT30R group), there was no increase in infarct size relative to the Vehicle group.
To determine whether the mass of the LV influenced the mass of the Ar from coronary occlusion, the A, was correlated with the respective LV mass in each experiment (Fig 4, A) . (Single-dose SPTIR and PDR groups have been omitted for clarity.) All four groups had a similar range and distribution of LV mass as well as Ar and did not show any deviation from or clustering on the regression line. The equation for all data points was Ar (grams)=0.34(x)-0.068, where x=mass of the LV; the correlation between Ar and LV mass, 0.54, was poor. The relation between the mass of the An and mass of the Ar for individual groups is shown in Fig 4 An=0.4886(x)-0.0267 (r=.91); and SPT30R:
An=0.30(x)-0.009 (r=.84), where x=mass of the Ar. The slopes for MSPTIR and SPTR groups were comparable to each other and were significantly (P<.05) greater than the slopes for Vehicle and SPT3OR. The Vehicle and SPT3OR groups had comparable slopes. Therefore, the larger infarct size in the MSPTIR and SPTR groups was not caused by a larger Ar but rather by their relative interventions.
Relation Between Infarct Size and Transmural Myocardial Blood Flow
Infarct size data are correlated with transmural collateral blood flow in the Ar in Fig 5. The An/Ar versus collateral blood flow relation in the Vehicle group had a slope of -0.61 and an intercept of 30.4% An/Ar. SPT given in multiple doses at ischemia/reperfusion (MSPTIR) or at the onset of reperfusion (SPTR) displaced the linear relation upward with a near doubling of the intercept to 58.5% An/Ar and 47.9% An/Ar (P<.05 versus Vehicle), respectively. Therefore, SPT given at these times increased infarct size by a mechanism independent of altering collateral blood flow. Delay in adenosine receptor blockade until 30 minutes of reperfusion (SPT3OR) produced a downward shift with a slope of -0.84 and an intercept of 31.9% in the 
Discussion
Adenosine accumulates and is released in large quantities during myocardial ischemia and hypoxia when the myocardial oxygen supply-and-demand status is in severe imbalance.20 Numerous studies have shown that exogenous adenosine given intravenously or intracoronarily in pharmacological doses is cardioprotective.4,6-8 However, the cardioprotective role of endogenous adenosine is less clear. The primary cytoplasmic source of endogenous adenosine in the heart is the cardiomyocyte, with less adenosine originating from the endothelium. 21 Previous studies have focused on the modulation of metabolic and physiological responses by endogenous adenosine during low-flow global ischemia and coronary occlusion. Angello et a122 demonstrated that endogenous adenosine released during ischemia enhanced metabolic recovery of isolated perfused rat hearts. In addition, endogenous adenosine was found to inhibit the exocytotic release of norepinephrine23 and decrease platelet aggregation after coronary occlusion. 24 Whether these metabolic and anti-inflammatory effects of endogenous adenosine could act in a cardioprotective manner during reversible ischemia is not known.
The present study extends our knowledge of the cardioprotective role played by adenosine by demonstrating that blockade of the interaction between endogenous adenosine and adenosine receptors could significantly modulate (increase) infarct size. As might be expected, the beneficial effects of endogenous adeno- enous adenosine in the pathogenesis of myocardial infarction and microvascular perfusion injuries ("lowreflow" phenomenon) by adenosine receptor-mediated mechanisms. The effects of SPT at ischemia/reperfusion were dose-dependent, since multiple infusions of SPT during the ischemic and reperfusion periods resulted in a larger infarct size than when SPT was given as a single bolus. Interrupting receptor-mediated events during reperfusion, when the presence of adenosine is ephemeral because of washout by reactive hyperemia, catabolism via adenosine deaminase, and transport out of the tissue, resulted in infarct size that was 87% of that found when blocking receptors during both ischemia and reperfusion (MSPTIR group). Permitting adenosine receptor-mediated events to proceed during the first 30 minutes of reperfusion decreased both the infarct size and perfusion abnormalities to values comparable to the Vehicle group. These data suggest that (1) endogenous adenosine assumes an important cardioprotective role, (2) the majority of the total receptormediated cardioprotection by endogenous adenosine is expressed predominantly during reperfusion, and (3) a significant portion of reperfusion injury addressed by autacoid adenosine is expressed during the first 30 minutes of reflow. Although previous studies suggest that the beneficial effects of adenosine are dependent Blockade during ischemia and reperfusion (MSPTIR) or only during reperfusion (SPTR) shifted the lines upward with significant increases in ordinate intercepts, suggesting that blockade in these groups increased infarct size independent of blood flow during ischemia. MSPTIR intravenous SPT in multiple doses during ischemia and early reperfusion; SPTR intravenous SPT before reperfusion; SPT30R intravenous SPT after 30 minutes of reperfusion; VEH, Vehicle. on lidocaine,25 the cardioprotective effects of endogenous adenosine observed in this study as well as in a previous study13 were independent of lidocaine. The increase in infarct size seen with SPT administered before ischemia is in contrast to data reported by Liu et al. 26 In the present study, however, there was a tendency for SPT given before ischemia to increase infarct size (approximately 52% An/Ar) compared with Vehicle (39% An/Ar), but this difference in infarct size did not reach statistical significance. The difference between the present study and that of Liu et a126 may be related to (1) the lower dose of SPT used by that group (7.5 mg/kg), (2) the large variability in their data relative to our data, and (3) the use of sodium pentobarbital anesthetic as opposed to ketamine and xylazine, which results in higher heart rates. 8-p-Sulfophenyltheophylline, a water-soluble xanthine derivative that is nonspecific for A1 or A2 subtypes, is relatively equipotent for A1 and A2 receptor subtypes, having a Ki of 4.5 and 6.3 gmol/L for the A1 and A2 receptors, respectively,16 and is more potent as an adenosine antagonist than is theophylline. SPT does not interfere with the release of adenosine by the myocardium; therefore, adenosine is present in the tissue and is washed out by the coronary venous effluent. 22 Our data would support that cardioprotection during ischemia and reperfusion is a receptor-mediated event rather than an alteration of some other adenosine-regulating mechanism. The main advantage of SPT is that the p-sulfophenyl moiety prevents the antagonist from entering the cardiac myocyte, thereby blocking the extracellular adenosine receptors without interfering with intracellular phosphodiesterase activity. To rule out the possibility that the increased infarct size in the SPTtreated groups (MSPTIR, SPTIR, SPTR) was a direct effect of SPT independent of adenosine receptor blockade, we used a nonxanthine, nonselective A1-A2 adenosine receptor antagonist, PD115,199. Similar results were found after infusions of PD115,199 just before v l n1 reperfusion was begun, as we found with the SPTR group, suggesting that the effects of SPT were not caused by a receptor-independent mechanism. In addition, SPT given 30 minutes into reperfusion did not increase infarct size. According to bioassay data presented by Liu et al,26 7.5 mg/kg SPT was a sufficient dose to block the A2-mediated hypotensive response to an intravenous adenosine challenge for approximately 45 minutes, after which the blockade was gradually reversed. To rule out such decreasingly effective levels of SPT, we infused SPT from the onset of coronary occlusion (10 mg/kg as first dose, then 5 mg/kg as second and third doses every 20 minutes) until 10 minutes after reperfusion in the MSPTIR group. This multidose regimen was associated with a 14% larger infarct size than in the single-dose SPTIR group, suggesting that antagonism in the singledose SPTIR group waned during the ischemia/reperfusion period, thus permitting some adenosine receptor interaction to occur, with a consequent smaller infarct size relative to the multiple-dose group. However, SPT antagonism in the SPTR group should have been sufficient to interrupt adenosine receptor interactions during at least the initial 30 minutes of reperfusion when cardioprotection was apparently expressed.
Results of the present study suggest, first, that the cardioprotective actions of endogenous adenosine were expressed primarily during early reperfusion, which was confirmed when adenosine was allowed to exercise interaction with receptors in the SPT3OR group with resultant infarct size comparable to the Vehicle group, and second, that SPT itself had no direct effect on infarct size. This is consistent with the observations made by Angello et al22 that the metabolic expression of cardioprotection of adenosine was manifest during the reperfusion phase. In Angello et al's study, the abnormal metabolic effects secondary to adenosine receptor blockade with SPT were much more pronounced during reperfusion than ischemia, suggesting that endogenous adenosine acts predominantly during reperfusion or, alternatively, attenuates ischemic events that are manifest only after reperfusion. It is not clear from our study whether the cardioprotection afforded by adenosine during reperfusion is dependent on its presence during early reperfusion or whether cardioprotection is an expression of processes related to the presence of adenosine during ischemia. Although adenosine is rapidly washed out during reperfusion, there may still be a sufficient quantity present during the early moments to exert cardioprotection.
A cardioprotective function of exogenous adenosine resulting in significant reduction in infarct size has been demonstrated in a number of recent reports. Olafsson et a17 demonstrated that adenosine infused intracoronarily during the first hour of reperfusion at 3.75 mg/min reduced infarct size by 31%. Subsequent studies have confirmed similar infarct size reduction after 120 minutes of occlusion6 but not after more prolonged durations of regional ischemia. 27 Similar infarct size reduction, independent of negative chronotropy and hypotension, was noted with intravenous administration of adenosine during reperfusion.8 '15 In addition, administration of adenosine before ischemia13,26 resulted in infarct size reduction. Although the majority of these study by Toombs et a113 and results from the present study demonstrate cardioprotection independent of lidocaine, in contrast to Homeister et al. 25 However, opposing these purported cardioprotective effects are the observations of Goto et al, 28 who recently reported that adenosine infusion in the presence or absence of lidocaine failed to alter the extent of acute (3 hours of reperfusion) or late (72 hours of reperfusion) development of infarction. The present study clearly showed that interruption of endogenous adenosine receptor interaction during ischemia or early reperfusion increased infarct size independent of lidocaine.
The weight of evidence to date suggests that the cardioprotective actions of parenterally administered adenosine, culminating in reduction of infarct size, amelioration of microvascular injury, and preservation of postischemic perfusion to the area at risk, are exerted during ischemia413 as well as during reperfusion. [6] [7] [8] 15 The cardioprotection exerted by parenteral adenosine during reperfusion may be related to the supraphysiological doses given in those studies. The present study supports such a chronology of cardioprotection for endogenous adenosine, and we would submit further that (1) this chronology may represent two phases of receptor-mediated activity expressed to differing degrees in ischemia and during reperfusion and (2) the amount of adenosine endogenously released during ischemia/reperfusion is sufficient to exert cardioprotection during ischemic and reperfusion time periods. The chronology of protection observed in the present study, with significant cardioprotection exerted during ischemia/reperfusion but with the predominant (75% of total cardioprotection, assuming that MSPTIR blocked 100% of the response) effect exerted during reperfusion, may be related to different mechanisms recruited by A1-receptors and A2-receptors during the phases of ischemia and reperfusion. Activation of the adenosine A,-type receptor inhibits adenylate cyclase and produces a decrease in cyclic AMP with negative chronotropic, dromotropic,229 and inotropic effects, as well as activation of ATP-sensitive potassium (KATP) channels. 30 When SPT was used to block adenosine receptors during both ischemia and reperfusion (MSPTIR group), the blockade of the A, receptor subtype may have antagonized activation of ATP-sensitive potassium channels, which are coupled to the A, receptor subtype via G protein, with resulting increase of the severity of ischemia31 as well as blocking effects during reperfusion. A large infarct size relative to the SPTR group would be expected, because the severity of ischemia in part determines the intensity of reperfusion sequelae. On the other hand, SPT blockade of adenosine A2-receptor activation would blunt coronary vasodilation and neutrophil inhibition. Neutrophil-mediated events seem to predominate during this reperfusion rather than during ischemia.32-34 Thornton et a114 demonstrated that A,receptor activation with [N6-1-(phenyl-2R-isopropyl]adenosine (R-PIA) during reperfusion had no effect on infarct size. In contrast, Norton et al15 reported participation of both A,and A2-mediated events during reperfusion. However, the observations of Norton et al may represent dose-dependent effects achieved with large doses of exogenous adenosine that may not pertain to the actions of lower in vivo tissue levels of endogenous studies used lidocaine to attenuate arrhythmias, the adenosine. According to our hypothesis, endogenous adenosine would exert modest (25% of total) cardioprotection by A,-mediated mechanisms, whereas predominant (75% of total) cardioprotection would be exerted during reperfusion by primarily A2-mediated mechanisms. A preliminary study from our laboratory confirms modest A,-mediated protection by endogenous adenosine during ischemia.35 However, confirmation of these proposed mechanisms underlying the chronology of cardioprotection by endogenous adenosine in the present study must await receptor subtype-selective antagonism of endogenous adenosine.
It is clear from Table 1 that there was a steady decline in mean arterial blood pressure during the course of the experiment. This observation raises the question of whether these low pressures may have compromised perfusion to the myocardium and hence contributed to the development of necrosis. We did not measure subendocardial blood flow specifically in this study; therefore, we cannot rule out the possibility that subendocardial perfusion was affected by low perfusion pressures. However, there was no difference in mean arterial blood pressure between groups, ruling out group-specific differences. In addition, transmural blood flow was restored to control levels in the Vehicle and SPT3OR groups, ruling out pressure-limited perfusion.
In the present study, myocardial blood flow in the A, showed a reactive hyperemia at 15 minutes of reperfusion in the two groups in which adenosine receptors were unblocked (Vehicle and SPT3OR). There was a progressive decrease in blood flow over the 2-hour reperfusion period to near control levels (noninfarcted tissue) or slightly below control levels (infarcted tissue). In contrast, in the groups in which adenosine receptors were blocked during the entire reperfusion period (MSPTIR, SPTR), the reactive hyperemic response was significantly blunted, and 2-hour blood flow deteriorated to significantly below the Vehicle group, consistent with a "low reflow" in infarcted and noninfarcted tissue. The blunting of reactive hyperemia with SPT is consistent with and lends support to the role of endogenous adenosine in partially mediating this transient vasodilator response.136 More importantly, the significantly depressed postischemic (2 hours of reperfusion) regional blood flow to the area at risk in the MSPTIR and SPTR groups may suggest that endogenous adenosine has an important role in attenuating microvascular perfusion defects which, if it is withdrawn, leads to exaggerated impairment and an exaggerated "no-reflow" condition as defined by Becker et al.37 The data by Vinten-Johansen et a138 suggest that the blunting of hyperemia per se did not contribute to the larger infarcts found in the MSPTIR, SPTIR, and SPTR groups. In fact, that study showed that blunting of the reactive hyperemic phase of reperfusion was associated with a decrease in infarct size.38 Although a portion of this microvascular perfusion injury may occur during the ischemic period, a large component is either expressed or exaggerated with reperfusion and may therefore be considered one manifestation of reperfusion injury.37'38 A corollary of this hypothesis is that the degree of perfusion defect can be modified by reperfusion interventions.7'8'38 Toombs et al13 showed that a brief pretreatment bolus of exogenous adenosine improved postischemic blood flow in the A, compared with less postischemic blood flow in an untreated group.
Others6-8 have also shown that parenteral adenosine improved postischemic blood flow in the ischemic/ reperfused myocardium and avoided postischemic "noreflow." In the present study, postischemic perfusion defects in the ischemic/reperfused myocardium may represent either loss of adenosine-mediated vasodilator reserve with SPT or a pathological cause. We did not test the vasodilator reserve in this experiment and therefore cannot comment on impaired vasodilation by blockade of adenosine A2 receptors. However, the nonischemic region showed no indication of loss of adenosine-modulated perfusion. The mechanism(s) by which endogenous adenosine avoided pathologically impaired postischemic blood flow may involve inhibition of neutrophil-mediated microvascular injury and microvascular embolization.6,7 It is not clear whether the infarct size-limiting effects of endogenous adenosine are related to this prevention of postischemic blood flow defects.
In conclusion, we found that endogenous adenosine, released from the myocardium during coronary occlusion and perhaps early reperfusion, exerted some cardioprotection during the ischemic period but exerted approximately 75% of its total cardioprotection during the early phase of reperfusion, which was not related to lidocaine treatment. The present findings and the results of others4"3'35 suggest that the release of endogenous adenosine, acting via receptors, represents an inherent cardioprotective mechanism that may be important in preserving myocardial blood flow and reducing infarct size after ischemia and reperfusion. These results provide a rationale for pharmacologically augmenting myocardial adenosine levels by increasing adenosine production with agents such as AICA-ribo-side4 or adenosine deaminase inhibitors such as 2-deoxycoformycin administered before ischemia, during ischemia, or during reperfusion in patients undergoing percutaneous transluminal angioplasty, elective coronary artery bypass surgery, or thrombolysis. In addition, we predict a new role for adenosine as an endogenous defense autacoid against reperfusion injury.
